Tuesday, Scotiabank (TSX:BNS) updated its price target for Disc Medicine (NASDAQ: IRON) shares, increasing it to $70 from $62, while retaining a Sector Outperform rating. The adjustment follows Disc Medicine's positive feedback from the FDA concerning its phase 3 trial for bitopertin, a treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
The analyst from Scotiabank noted the end-of-phase 2 FDA meeting as a significant success, with agreement on all proposed endpoints for the upcoming phase 3 trial. The chosen primary endpoint, which measures the average monthly time in sunlight during the last month after a 6-month treatment period, is expected to address the high placebo response observed in the phase 2 AURORA study.
Disc Medicine has also announced the possibility of seeking accelerated approval based on the existing data, which could substantially shorten the time to market for bitopertin. The treatment's potential for significant market share is attributed to its oral administration and its targeted approach to addressing the root cause of EPP/XLP.
The Scotiabank analyst forecasts sales of bitopertin to reach $889 million by 2034 in the EPP/XLP market, surpassing the consensus estimate of $674 million. The updated price target to $70 reflects a revised probability of success (PoS), increased from the previous 60%.
In other recent news, Disc Medicine has seen a wave of activity with significant developments in its operations. The company's stock target was upgraded by BMO Capital Markets to $112, following a positive regulatory update for bitopertin, a treatment in development for erythropoietic protoporphyria (EPP). Similarly, Raymond (NS:RYMD) James elevated Disc Medicine's stock from Outperform to Strong Buy, setting a new price target of $110.00.
The company has received positive feedback from the FDA regarding bitopertin, leading to an expectation of approval through an accelerated pathway. Disc Medicine also announced a public stock offering of approximately $178 million to advance research and clinical development of its product candidates.
On the personnel front, Disc Medicine welcomed Dr. Rahul Rajan Kaushik as Chief Technical Officer and Dr. Steve Caffé as Chief Regulatory Officer, both with over two decades of experience in the pharmaceutical industry.
Furthermore, the company reported encouraging results from its Phase 1b study of DISC-0974, showing significant reduction in hepcidin levels and improvement in iron mobilization and hemoglobin levels in patients with non-dialysis-dependent chronic kidney disease and anemia. These developments underscore Disc Medicine's continuous efforts to advance its clinical trials and operations.
InvestingPro Insights
Disc Medicine's recent positive FDA feedback and Scotiabank's upgraded price target are reflected in the company's strong market performance. InvestingPro data shows that Disc Medicine has experienced significant returns, with a 26.91% increase in the past week and a 95.54% surge over the last six months. This aligns with the analyst's optimistic outlook on the company's potential in the EPP/XLP market.
Despite these positive signals, InvestingPro Tips caution that Disc Medicine is not currently profitable, with a negative P/E ratio of -18.76 for the last twelve months as of Q2 2024. Additionally, the company's RSI suggests the stock may be in overbought territory, which investors should consider when evaluating the recent price surge.
For a more comprehensive analysis, InvestingPro offers 13 additional tips for Disc Medicine, providing deeper insights into the company's financial health and market position. These additional tips can help investors make more informed decisions about the potential of Disc Medicine's innovative treatments and its market prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.